Hematologic Malignancy
Lymphoid Leukemia
CI-CAN-00001101Explore in graph →
Hematologic827 active trials20 approved drugs95 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001101Explore in graph →
Clinical trials
3,262 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (489)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00588991 | Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders | completed | Phase 1 | 12 | National Cancer Institute (NCI)NIH | 1 | Apr 2, 2025 | clinicaltrials |
| NCT03792256 | Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL) | completed | Phase 1 | 12 | Children's Oncology GroupNETWORK | 1 |
| Mar 21, 2025 |
| clinicaltrials |
| NCT05225584 | Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors | completed | Phase 1 | 56 | Kymera Therapeutics, Inc.INDUSTRY | 1 | Mar 19, 2025 | clinicaltrials |
| NCT06865352 | Safety and Preliminary Efficacy of Donor-derived Anti-leukemia Cytotoxic T Lymphocytes for the Prevention of Leukemia Relapse in Children Given Haploidentical Hematopoietic Stem Cell Transplantation | completed | Phase 1 / Phase 2 | 15 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT03088878 | A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies | completed | Phase 1 / Phase 2 | 95 | Oncternal Therapeutics, IncINDUSTRY | 1 | Feb 12, 2025 | clinicaltrials |
| NCT01638533 | Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction | completed | Phase 1 | 37 | National Cancer Institute (NCI)NIH | 2 | Feb 7, 2025 | clinicaltrials |
| NCT03751709 | Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL | completed | Phase 1 | 22 | Cedars-Sinai Medical CenterOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT05775406 | Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors | completed | Phase 1 | 52 | Kymera Therapeutics, Inc.INDUSTRY | 1 | Jan 27, 2025 | clinicaltrials |
| NCT03997968 | A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 169 | Cyteir Therapeutics, Inc.INDUSTRY | 1 | Dec 24, 2024 | clinicaltrials |
| NCT04688385 | Personalized Multi-peptide Vaccination in CLL Patients | completed | Phase 1 | 20 | University Hospital TuebingenOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT02924402 | Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies | completed | Phase 1 | 154 | Xencor, Inc.INDUSTRY | 4 | Nov 13, 2024 | clinicaltrials |
| NCT03524235 | Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL | completed | Phase 1 | 20 | Noah MerinOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT03989466 | Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia | completed | Phase 1 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 10, 2024 | clinicaltrials |
| NCT04450069 | CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies | completed | Phase 1 | 18 | Calibr, a division of Scripps ResearchOTHER | 1 | Aug 20, 2024 | clinicaltrials |
| NCT05326516 | A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia | completed | Phase 1 | 30 | Syndax PharmaceuticalsINDUSTRY | 2 | Aug 13, 2024 | clinicaltrials |
| NCT06527781 | A Study of PD5K3 in Healthy Adult Volunteers | completed | Phase 1 | 28 | Chongqing Peg-Bio Biopharm Co., Ltd.INDUSTRY | 1 | Jul 30, 2024 | clinicaltrials |
| NCT02920697 | Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma | completed | Phase 1 | 65 | Institut de Recherches Internationales ServierOTHER | 8 | Jul 25, 2024 | clinicaltrials |
| NCT01523977 | Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL(CRAD001NUS175T) | completed | Phase 1 | 22 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 18, 2024 | clinicaltrials |
| NCT04969601 | Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings(PACIFIC) | completed | Phase 1 / Phase 2 | 76 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT03892044 | Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma | completed | Phase 1 | 7 | David Bond, MDOTHER | 1 | May 2, 2024 | clinicaltrials |
| NCT00457782 | A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's Lymphoma | completed | Phase 1 | 27 | Kyowa Kirin Co., Ltd.INDUSTRY | 1 | Apr 25, 2024 | clinicaltrials |
| NCT04524455 | Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relapsed or Refractory B Cell Precursor ALL | completed | Phase 1 | 17 | AmgenINDUSTRY | 9 | Apr 8, 2024 | clinicaltrials |
| NCT01588015 | Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant | completed | Phase 1 | 36 | City of Hope Medical CenterOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT03056339 | Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies | completed | Phase 1 / Phase 2 | 49 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 25, 2024 | clinicaltrials |
| NCT01386619 | NK DLI in Patients After Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation (HSCT) | completed | Phase 1 / Phase 2 | 15 | University Hospital, Basel, SwitzerlandOTHER | 2 | Mar 19, 2024 | clinicaltrials |
| NCT04557436 | TT52CAR19 Therapy for B-cell Acute Lymphoblastic Leukaemia (B-ALL)(PBLTT52CAR19) | completed | Phase 1 | 9 | Great Ormond Street Hospital for Children NHS Foundation TrustOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT02168140 | CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma | completed | Phase 1 | 16 | Wake Forest University Health SciencesOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT03964259 | Reduced IV Fluids to Improve Clearance of HDMTX in Children w/Lymphoma or Acute Lymphoblastic Leukemia | completed | Phase 1 | 10 | Virginia Commonwealth UniversityOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT01041508 | Clofarabine and Low Dose Total Body Irradiation as a Preparative Regimen for Stem Cell Transplant in Leukemia. | completed | Phase 1 | 18 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 1 | Feb 1, 2024 | clinicaltrials |
| NCT03833180 | A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001) | completed | Phase 1 | 91 | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Jan 12, 2024 | clinicaltrials |
| NCT03919526 | Anti-CD19/CD22 Bispecific Chimeric Antigen Receptor（CAR)-T Cell Therapy for Measurable Residual Disease(MRD) Positive ALL | completed | Phase 1 | 19 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Dec 8, 2023 | clinicaltrials |
| NCT00697684 | Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant | completed | Phase 1 | 29 | Beth Israel Deaconess Medical CenterOTHER | 1 | Nov 28, 2023 | clinicaltrials |
| NCT01523223 | Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies | completed | Phase 1 | 16 | Robert LowskyOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT00047060 | Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome | completed | Phase 1 / Phase 2 | 5 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Nov 14, 2023 | clinicaltrials |
| NCT02916979 | Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG(FluBuATG) | completed | Phase 1 | 20 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Oct 18, 2023 | clinicaltrials |
| NCT02122081 | Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies | completed | Phase 1 | 33 | Sumithira VasuOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT03010358 | Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 24 | Alexey Danilov, MDOTHER | 1 | Aug 8, 2023 | clinicaltrials |
| NCT01614197 | A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma | completed | Phase 1 | 16 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 3 | Jul 27, 2023 | clinicaltrials |
| NCT03019055 | Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell | completed | Phase 1 | 26 | Medical College of WisconsinOTHER | 1 | Jul 27, 2023 | clinicaltrials |
| NCT03328104 | Everolimus in Combination With Nelarabine, Cyclophosphamide and Etoposide in Lymphoblastic Leukemia/Lymphoma(ENCERT) | completed | Phase 1 | 8 | Emory UniversityOTHER | 1 | Jul 21, 2023 | clinicaltrials |
| NCT03991884 | Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia | completed | Phase 1 | 24 | University of WashingtonOTHER | 1 | Jul 6, 2023 | clinicaltrials |
| NCT01029366 | CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy | completed | Phase 1 | 26 | University of PennsylvaniaOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT02141828 | A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene | completed | Phase 1 | 18 | Epizyme, Inc.INDUSTRY | 2 | Jun 18, 2023 | clinicaltrials |
| NCT00481091 | A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia | completed | Phase 1 / Phase 2 | 60 | AbbVieINDUSTRY | 4 | Jun 13, 2023 | clinicaltrials |
| NCT03236857 | A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies | completed | Phase 1 | 143 | AbbVieINDUSTRY | 8 | May 22, 2023 | clinicaltrials |
| NCT03389035 | Transposon-manipulated Allogeneic CARCIK-CD19 Cells in Pediatric and Adult Patients With r/r ALL Post HSCT(CARCIK) | completed | Phase 1 / Phase 2 | 21 | Fondazione Matilde Tettamanti Menotti De Marchi OnlusOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT01925131 | S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia | completed | Phase 1 | 50 | SWOG Cancer Research NetworkNETWORK | 1 | May 3, 2023 | clinicaltrials |
| NCT02185781 | Phase I Study of Adoptive Immunotherapy With Enriched and Expanded Autologous Natural Killer (NK) Cells for Patients With Ph+ Acute Lymphoblastic Leukemia (ALL) | completed | Phase 1 | 6 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Mar 30, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Apr 2, 2025source: clinicaltrials